L2167

L-165,041

≥98% (HPLC), powder

• Synonym(s): 4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy­acetic acid
• Empirical Formula (Hill Notation): C₂₂H₂₆O₇
• CAS Number: 79558-09-1
• Molecular Weight: 402.44
• MDL number: MFCD04974501
• UNSPSC Code: 12352200
• PubChem Substance ID: 24278477
• NACRES: NA.77

Properties

• Quality Level: 100
• Assay: ≥98% (HPLC)
• form: powder
• storage condition: protect from light; under inert gas
• color: off-white
• mp: 127-128 °C (lit.)
• solubility: DMSO: >10 mg/mL
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: CCCc1c(O)c(ccc1OCCCOc2ccc(OCC(O)=O)cc2)C(C)=O
• InChI: 1S/C22H26O7/c1-3-5-19-20(11-10-18(15(2)23)22(19)26)28-13-4-12-27-16-6-8-17(9-7-16)29-14-21(24)25/h6-11,26H,3-5,12-14H2,1-2H3,(H,24,25)
• InChI key: HBBVCKCCQCQCTJ-UHFFFAOYSA-N
• Gene Information: human ... PPARD(5467)

Description

Application

L-165,041 has been used as a peroxisome proliferator-activated receptor β/δ (PPARβ/δ) ligand to study its influence on PPARβ/δ mediated postnatal myogenesis in C2C12 myoblasts.

Biochem/physiol Actions

L-165041 dose-dependently blocks rat vascular smooth muscle cell (VSMC) proliferation and migration by inducing the cell cycle arrest. It has the potential to treat pathological cardiovascular conditions, such as restenosis and atherosclerosis. L-165041 also effectively inhibits the progression of diabetic nephropathy. It exhibits anti-apoptosis and anti-angiogenic effects.

PPARβ (PPARδ) selective agonist.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Safety Information

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves